124 related articles for article (PubMed ID: 37002181)
1. Pre-emptive resection for intraductal papillary mucinous neoplasia - Long-term outcome is similar between non-invasive and early invasive lesions in a tertiary single center.
Djoumi Y; Sadr-Azodi O; Vujasinovic M; Del Chiaro M; Sparrelid E; Ghorbani P; Holmberg M
Pancreatology; 2023 Jun; 23(4):389-395. PubMed ID: 37002181
[TBL] [Abstract][Full Text] [Related]
2. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
[TBL] [Abstract][Full Text] [Related]
3. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
4. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
6. Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance.
Kim HS; Han Y; Kang JS; Choi YJ; Byun Y; Kim H; Lee KB; Kim H; Kwon W; Jang JY
Ann Surg; 2022 Oct; 276(4):e231-e238. PubMed ID: 32941274
[TBL] [Abstract][Full Text] [Related]
7. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
8. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
9. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
[TBL] [Abstract][Full Text] [Related]
11. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
13. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
[TBL] [Abstract][Full Text] [Related]
14. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
[TBL] [Abstract][Full Text] [Related]
16. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
18. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
19. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
20. Intraductal papillary mucinous neoplasm of pancreas: Clinicopathological features and long-term survival after surgical resection.
Revoredo Rego F; Reaño Paredes G; de Vinatea de Cárdenas J; Herrera Chávez G; Kometter Barrios F; Arenas Gamio J
Cir Esp (Engl Ed); 2023 Nov; 101(11):736-745. PubMed ID: 36716959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
